Lupin, India's fifth largest drug maker, announced the acquisition of Russia's Biocom, a fast-growing generic pharmaceuticals firm, for an undisclosed amount.
Lupin Chief Executive Officer, Vinita Gupta, said: "We are excited about our entry into the Russian market through Biocom. Russia is an attractive market and this acquisition will also enable our expansion into neighbouring markets as well as other Eastern European markets in the future."

